1. Dupilumab reduced itch and hive severity vs placebo in antihistamine-refractory chronic spontaneous urticaria.
2. Results replicated prior phase 3 findings from the CUPID-A trial.
3. More patients achieved controlled disease, including UAS7 ≤6 and complete response.
4. Clinical improvement appeared by week 3 and persisted through week 24.
5. Safety was similar to placebo, with no new safety signals.

Source: JAMA Dermatology